Genetic variant in SM linked to higher risks during venom immunotherapy
Patients with SM and venom allergies may face increased risks during immunotherapy if they have a particular genetic variant.
Patients with SM and venom allergies may face increased risks during immunotherapy if they have a particular genetic variant.
Patients with advanced mastocytosis showed significantly higher sclerostin concentrations, especially in those with bone disease.
Improved diagnostics resulted in a higher prevalence of mastocytosis, including SM, than earlier reported, a new study said.
Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.
RNA-based testing significantly enhanced the detection of KIT mutations, which is critical for diagnosing systemic mastocytosis.
A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.
More than half of patients with indolent systemic mastocytosis reported mild or worse quality of life issues.
Mastocytosis increased the risk of venom-induced anaphylaxis, but food and drug allergies were often overreported.
Intranasal epinephrine powder’s rapid absorption makes it a promising alternative to traditional epinephrine injections, a company said.
Vigilant monitoring of gastrointestinal health is crucial for patients with systemic mastocytosis to avoid complications, a new study finds.